Skip to main content

Major Depressive Disorder

The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for esketamine (Spravato) CIII nasal spray.
A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.
Adjunctive esketamine appears effective for patients with major depressive disorder (MDD) who are treatment-resistant or suicidal, a meta-analysis published in The Journal of Clinical Psychiatry concluded.
A novel vasopressin 1B (V1B) receptor antagonist eased depressive symptoms when used as an adjunctive treatment in patients with major depressive disorder (MDD) in a small phase 2 study in the Journal of Psychiatric Research.
People with low mood and a history of depression tend not to use mood-modifying activities to stabilize mood, according to research published online in JAMA Psychiatry.
Psych Congress Steering Committee member Charles Raison, MD, recently joined the Ottawa Institute of Cognitive Behavioural Therapy for an examination of depression through an evolutionary lens.
Two members of the Psych Congress Steering Committee have been featured on an ABC News podcast which grew out of a newsman's newfound interest in meditation.
Listen as Psych Congress Steering Committee member Charles Raison, MD, discusses a book he coauthored, The New Mind-Body Science of Depression, with David Van Nuys, PhD, on Shrink Rap Radio.
Listen to Charles Raison, MD, discuss his JAMA Psychiatry study examining the relationship between inflammation and depression.
Back to Top